After-hours movers: Akero Therapeutics gains ahead of data, PagerDuty falls on conv. offering
; will hold an investor conference on Tuesday, October 10 at 8:00 a.m. ET to share topline week 36 results from its SYMMETRY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin in patients with compensated cirrhosis due to non-alcoholic steatohepatitis .; intends to offer, subject to market conditions and other factors, $350 million principal amount of Convertible Senior Notes due 2028.
{username} Just Now Share Follow this postUnfollow this post Save Saved. See Saved Items . This comment has already been saved in your Saved Items Author's response{commentContent} Reply 00 Report {username} Just NowAuthor's response Share Follow this postUnfollow this post Save Saved. See Saved Items .
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
PagerDuty stock falls on new debt offeringWallace Witkowski came to MarketWatch from the Associated Press in New York, where he covered the business of Big Pharma, after covering FDA regulation of many of the same companies, as well as medical devices, in the Washington, D.C., area. Based in San Francisco, his current focus is on the more exciting world of semiconductors, videogames and cybersecurity, when he's not churning out earnings coverage. Follow him on Twitter at: wmwitkowski.
Read more »
Bristol Myers Squibb to buy cancer drugmaker Mirati Therapeutics in up to $5.8B dealBristol Myers Squibb will buy Mirati Therapeutics in a deal worth up to $5.8 billion, or $58 per share, the biopharmaceutical company announced Sunday.
Read more »
Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 BillionDeal expands pharmaceutical company’s portfolio of cancer drugs
Read more »
Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billionMirati develops commercial-stage oncology therapies, and through the deal, Bristol Myers Squibb will add lung-cancer medicine Krazati, among others, to its...
Read more »
Bristol-Myers Squibb to acquire Mirati in $5.8 billion dealBristol-Myers Squibb (BMY.N) on Sunday said it will acquire Mirati Therapeutics (MRTX.O) in a transaction that values the cancer drugmaker at up to $5.8 billion.
Read more »
Exxon, Chevron, Mirati, Disney, Lockheed, and More Stock Market MoversExxon and Chevron shares rise after a surge in oil prices following the weekend attack on Israel from Hamas, Mirati Therapeutics stock falls after Bristol...
Read more »